備註請放最後面 違者新聞文章刪除
1.媒體來源:
外媒
marketwatch
2.記者署名:
By Tomi Kilgore
3.完整新聞標題:
Eli Lilly to supply the U.S. government with doses of COVID-19 treatment
etesevimab for $330 million
4.完整新聞內文:
Eli Lilly to supply the U.S. government with doses of COVID-19 treatment
etesevimab for $330 million
Published: Sept. 15, 2021 at 6:53 a.m. ET
By Tomi Kilgore
Eli Lilly & Co. LLY, -2.05% announced Wednesday to sell 388,000 doses of
etesevimab, which has been authorized for emergency use as a COVID-19
treatment for $330 million. As part of the deal, about 200,000 doses of
etesevimab, which complements doses of bamlanivimab previously purchased by
the U.S. government, are expected to ship in the third quarter of 2021, with
the remaining doses to be shipped in the fourth quarter. "The recent increase
in COVID-19 cases has caused a substantial rise in the utilization of
monoclonal antibody drugs, particularly in areas of the country with low
vaccination rates," said Lilly's Chief Scientific and Medical Officer Daniel
Skovronsky. "Lilly developed bamlanivimab and etesevimab for administration
together, in anticipation of variants such as the highly contagious Delta
variant, which currently accounts for more than 98 percent of all identified
COVID-19 cases in the U.S." Eli Lilly's stock, which was still inactive in
premarket trading, has run up 38.1% year to date, while the S&P 500 SPX,
-0.57% has gained 18.3%.
Eli Lilly & Co. LLY, -2.05% 週三宣布以 3.3 億美元的價格出售 388,000 劑
etesevimab，該藥已被授權緊急用作 COVID-19 治療。作為交易的一部分，約 200,000
劑 etesevimab 補充美國政府先前購買的 bamlanivimab 劑量，預計將於 2021 年第三季
度發貨，其餘劑量將在第四季度發貨。
“最近 COVID-19 病例的增加導致單基因複製抗體藥物的使用大幅增加，特別是在該國
疫苗接種率低的地區，”禮來公司的首席科學和醫學官 Daniel Skovronsky 說。
“禮來開發了 bamlanivimab 和 etesevimab 用於聯合給藥，預防出現變異，
例如高傳染性的 Delta 變異， 斯必克， -0.57% 上漲了 18.3%。
5.完整新聞連結 (或短網址):
https://is.gd/XdoJ72
6.備註:
以色列打到第七針後終於看到盡頭了呢！順帶一提Etesevimab的藥源是中國，看來解鈴
還需繫鈴人，藥頭總是最了解自己手上的貨呢！
https://imgur.com/jJxylCV
Etesevimab（LY-CoV016，又名JS016）最初由君實生物與中國科學院微生物所共同開發，
去年禮來從君實生物獲得授權，主導大中華地區以外全球地區的臨床開發。這兩款抗體均
靶向刺突蛋白受體結合域（RBD），但是靶向RBD的不同表位，因此組合療法可能產生更好
的治療效果。